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ABSTRACT
Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is associated 
with urinary tract symptoms and hormonal imbalances amongst others. The 
heterogeneous clinical presentation, unexplored molecular background and lack of 
prostate biopsies complicate therapy. Here, using liquid biopsies, we performed a 
comprehensive translational study on men diagnosed with CP/CPPS type III (n = 
50; median age 39.8, range 23–65) and age-matched controls (n = 61; median age 
36.8, range 20–69), considering biochemical parameters of blood and ejaculates, 
and epigenetic regulation of the estrogen receptor genes (ESR1 and ESR2) in 
leukocytes isolated from blood (systemic regulation) and in somatic cells isolated 
from ejaculates (local regulation). We found elevated 17β-estradiol (E2) levels in 
seminal plasma, but not in blood plasma, that was significantly associated with CP/
CPPS and impaired urinary tract symptoms. In ejaculated somatic cells of CP/CPPS 
patients we found that ESR1 and ESR2 were both significantly higher methylated 
in CpG-promoters and expressionally down-regulated in comparison to controls. 
Mast cells are reported to contribute to CP/CPPS and are estrogen responsive. 
Consistent with this, we found that E2 –treatment of human mast cell lines (HMC-1 
and LAD2) resulted in altered cytokine and chemokine expression. Interestingly, in 
HMC-1 cells, possessing epigenetically inactivated ESR1 and ESR2, E2 –treatment led 
to a reduced transcription of a number of inflammatory genes. Overall, these data 
suggest that elevated local E2 levels associate with an epigenetic down-regulation 
of the estrogen receptors and have a prominent role in CP/CPPS. Investigating E2 
levels in semen could therefore serve as a promising biomarker to select patients 
for estrogen targeted therapy. 
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INTRODUCTION
The prostate is particularly susceptible to disease, 
with ~90% of men developing histological benign 
prostatic hyperplasia (BPH) by the age of 80 [1], ~11.6% 
of all men developing prostate cancer (PCa) during 
their lifetime [2], and up to 16% developing chronic 
prostatitis/chronic pelvic pain syndrome (CP/CPPS) [3]. 
CP/CPPS generally receives less attention and remains 
poorly understood, even though it has a high disease 
burden. CP/CPPS is characterized by pelvic pain, ongoing 
urinary tract symptoms without detectable pathogens 
or identifiable aetiology, and various other signs and 
symptoms, assigning the syndrome to the class of chronic 
inflammatory and perhaps autoimmune disorders [4]. 
There is currently no reliable biomarker for CP/
CPPS. Instead, classification as inflammatory (IIIa: 
leukocytes) or non-inflammatory (IIIb: no leukocytes) is 
based on upon the presence or absence of leukocytes in 
expressed prostatic secretions or post prostatic massage 
urine [5]. However, this classification does not have 
implications for differential treatment [6], nor does the 
presence of leukocytes in prostatic secretions correlate 
with severity of symptoms [7]. Instead, it was the 
introduction of a multimodal treatment system (UPOINT) 
with symptom-specific patient stratification that has led 
to significant advances in disease management [8, 9], 
indicating that multiple disease entities could be concealed 
behind the diagnosis CP/CPPS. Nevertheless, the lack 
of reliable biomarkers and well-established patho-
mechanisms are the reasons why the syndrome is treated 
in a phenotype-directed manner. The high prevalence and 
morbidity of CP/CPPS, as well as the possible link to PCa 
and/or BPH upon aging, stresses the need for a deeper 
understanding of the underlying mechanisms. 
Steroid sex hormones, particularly testosterone 
and estradiol (E2), play key roles in the development and 
maintenance of the reproductive systems. The synthesis 
of estrogens from androgens is catalyzed by aromatase. 
Estrogen action in the male is viewed in at least two 
different ways: systemic endocrine effects acting through 
the pituitary gland to indirectly lower androgens and local 
effects that directly target prostate tissue by estrogen 
receptors [10]. Androgen and estrogen signaling plays 
a significant role in normal and abnormal growth of 
the prostate gland [10]. Studies examining the steroid 
hormones in CP/CPPS, however, are equivocal, reporting 
either elevated systemic testosterone and unchanged 
estradiol levels [11], or elevated systemic estradiol levels, 
but unchanged testosterone levels [12]. In the latter, it 
is interesting to note that this patient cohort also had an 
elevated body mass index, so adipose aromatase activity 
could account for the elevated systemic estradiol levels. 
Prostate biopsies in patients with CP/CPPS are not 
routinely performed, which has led to the development 
of multiple animal models such as experimental 
autoimmune prostatitis (EAP). These include mouse 
models of chronic prostatic inflammation induced by 
immunization with prostate antigen (PAg) [13], rat 
models with chronic inflammation induced by combined 
testosterone and E2 treatment [14], or a transgenic mouse 
model with aromatase (ARO+) over-expression leading 
to chronic prostatitis and prostate pre-malignancy with 
increased mast cell infiltration [15]. Further studies have 
subsequently linked mast cell infiltration and prostatic 
estrogen dominance to prostate cancer [16]. Elevated 
tryptase levels were also present in the expressed prostatic 
secretions (EPS) of CP/CPPS patients [17], underscoring 
the clinical significance of mast cells and drawing 
attention to estrogen as a potential mediator of both PCa 
and CP/CPPS. 
At least two compounds targeting estrogen signaling 
have been studied for treatment of CP/CPPS. Patients were 
shown to profit by treatment of Mepartricin, an estrogen 
reabsorption inhibitor [18], but also from quercetin, a 
plant isoflavonoid with anti-estrogenic properties and a 
~9 fold higher affinity to estrogen receptor beta (ERβ, 
ESR2 gene) than to ER-alpha (ERα, ESR1 gene) [19–21].
It is interesting to note that ERβ is a potent suppressor 
of inflammation in multiple tissues/organs, including the 
brain and bowel [22, 23]. Hence, an aberrant and increased 
prostatic ERα:ERβ ratio may contribute to CP/CPPS.
Administration of the histone deactelyase (HDAC) 
inhibitor MS-275 led to EAP attenuation in a rat model 
[24], highlighting the epigenetic dimensions of the 
inflammatory response as a possible target for epigenetic 
drugs. Our group recently reported epigenetic inactivation 
of CXCR4 (C-X-C motif receptor of the chemokine 
CXCL12/SDF1) in CP/CPPS patients’ liquid biopsies 
[25], showing that CP/CPPS is accompanied by systemic 
and organ-specific epigenetic changes. Here, we extend 
upon this and examine in a prospective analytical 
comparative study whether epigenetic aberrations of 
the sex hormone receptor genes ESR1, ESR2 and AR 
(androgen receptor) occur in CP/CPPS and associate with 
the clinical phenotype. This study was approved by the 
Ethics Commission of the Medical Faculty of the Justus-
Liebig-University Giessen (ethical votes, AZ.: 55/13; 
AZ.: 123/12) and all subjects provided written informed 
consent. To provide mechanistic insights for our findings 
in patients’ liquid biopsies, and to explore the role of mast 
cells and estrogen in CP/CPPS, we studied human mast 
cells and the influence of estrogen on their inflammatory 
profile. Overall, we provide new molecular insights into 
the chronification of prostatitis and demonstrate that 
seminal plasma estradiol levels and epigenetic state of 
estrogen receptor genes, respectively, may be a novel 
diagnostic tool for CP/CPPS patients that could be used to 
select patients for targeted therapy. 
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RESULTS 
Increased concentration of 17β-estradiol in 
seminal plasma is associated with CP/CPPS and 
impaired urogenital tract symptoms 
Whole blood and semen samples from CP/CPPS 
patients and healthy volunteers were analyzed in order to 
identify CP/CPPS associated systemic and local changes 
in sex hormone signaling (Figure 1). The median age 
of CP/CPPS patients was 39.76 years (range 23–65). 
As hormonal balance and imbalance, respectively, are 
age-dependent, an age-matched control cohort (median 
age 36.77, range 20–69) of healthy men without any 
preexisting urological conditions was also gathered (Figure 
1A.1). By considering CP/CPPS patients and controls 
together as well as by analyzing them separately, we did 
not find a correlation between age and 17β-estradiol (E2) 
concentrations in blood plasma (Figure 1A.2). A low 
positive correlation between age and E2 in seminal plasma 
(R2  = 0.145, p = 0.0316) was found exclusively in the 
CP/CPPS patient group (Figure 1A.3). Interestingly, only 
CP/CPPS patients, but not healthy controls, exhibited 
a strong correlation between E2 levels in blood and in 
seminal plasma (R2 = 0.35840, p = 0.0008) (Figure 1A.4). 
CP/CPPS patients and controls did not differ in blood 
E2 levels (36.45 ± 1.71 versus controls: 36.96 ± 1.73 
pg/ml; p > 0.05) (Figure 1B.1). However, E2 levels in 
seminal plasma were significantly increased in CP/CPPS 
patients compared to controls (CP/CPPS: 100.5 ± 3.72 
versus controls: 84.57 ± 4.09 pg/ml; p ≤ 0.01) (Figure 
1B.2). Further, the seminal plasma E2 concentrations 
were analyzed in patients and controls with regard to the 
chronic prostatitis symptom index (CPSI), an evaluation 
system for the severity of CP/CPPS which comprises the 
subscores for urinary tract (voiding) symptoms, pain and 
quality of life. Increased E2 concentrations in seminal 
plasma correlated with impaired urinary tract symptoms, 
when CP/CPPS patients and controls were analyzed 
together (R2 = 0.16; p = 0.0037) (Figure 1B.3). However, 
this trend was less pronounced in the individual groups 
(Figure 1B.4). The quality of life and pain scores, on the 
other hand, were not correlated with E2 concentrations in 
seminal plasma (Figure 1B.5; a scatter plot for the CPSI 
pain subscore and E2 is shown; see also Supplementary 
Figure 1).
Testosterone was routinely measured in the blood of 
CP/CPPS patients: Older patients (≥40 years) possessed 
significantly lower systemic testosterone levels compared 
to younger patients (≥40y: 315 ± 140 versus <40y: 458 ± 
288 pg/ml; p = 0.010) (Figure 1C.1). A significant positive 
correlation between blood testosterone and blood E2 was 
found in both age groups, whereby the correlation was 
more pronounced in younger patients (<40y: R2 = 0.37, 
p = 0.0044; ≥40y: R2 = 0.2483, p = 0.0155; Figure 1C.2). 
In younger patients, also a significant positive correlation 
between blood testosterone and E2 in seminal plasma was 
found (R2 = 0.2953, p = 0.0363; Figure 1C.3).
Semen samples are a source of inflammatory 
markers of CP/CPPS
Ejaculates of CP/CPPS patients and healthy controls 
were compared with regard to routine semen parameters 
(Supplementary Figure 1). In particular, significant 
impairments in ejaculate volume, sperm concentration, total 
number, motility, morphology and vitality of sperm cells 
and pH-value could be evaluated in CP/CPPS patients in 
comparison to healthy controls (Supplementary Figure 1). 
These subsequent results confirmed our previously 
described and discussed observations in CP/CPPS patients 
[25] and emphasized again the relation between CP/CPPS 
and impaired semen parameters. 
Seminal zinc, which is important for sperm motility 
amongst other functions, is mainly derived from prostatic 
secretions. The prostate fluid is known to be rich in 
citric acid, and the solubility of zinc increases with an 
increasing acidity. As CP/CPPS patients’ seminal plasma 
exhibited significantly decreased (more acidic) pH-values 
in comparison to controls (Figure 2A.1), we analyzed zinc 
levels in seminal plasma and its correlation to pH-values. 
Zinc concentrations per se were not changed in CP/
CPPS in comparison to controls (Figure 2A.2). However, 
a significant negative correlation between zinc and pH-
values could be observed in seminal plasma of CP/CPPS 
patients (R2 = –0.326, p < 0.0001) as well as controls 
(R2 = –0.2878, p = 0.0083) (Figure 2A.3). 
Human semen contains besides spermatozoa 
and immature germ cells also a variety of somatic 
cells, including epithelial cells from the male tract 
and leukocytes. Our previous study demonstrated that 
ejaculated somatic cells from CP/CPPS patients exhibited 
epigenetic aberrations in CXCR4 gene, a chemokine 
receptor often dysregulated in human tumors [25]. In 
order to get a more detailed profile of the white blood 
cells in ejaculates, we performed the peroxidase-positive 
leukocyte test and, additionally, an analysis of the 
expression of genes typical for inflammatory cells. We 
found that the number of peroxidase positive leukocytes 
was significantly increased in patients (Figure 2B.1). 
Somatic cells from the ejaculates of both CP/CPPS 
patients and healthy controls exhibited expression of 
aromatase (ARO, also estrogen synthase, is expressed in 
white blood cells), chymase (CMA1, mast cell marker) 
and PU.1 (transcription factor of lymphoid and myeloid 
hematopoietic cells) at different levels (Figure 2B.2, 2B.3 
and 2B.4). ARO and CMA1 gene expression levels were 
comparable in CP/CPPS patients and controls (p > 0.05) 
(Figure 2B.2 and 2B.3), whereas PU.1, although also 
not significantly different, showed a trend towards lower 
expression in patients (Figure 2B.4). The concentration of 
the chemokine interleukin-8 (IL-8) was also measured in 
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seminal plasma samples to evaluate the relationship of CP/
CPPS to inflammation. While not significant, a trend for 
increased IL-8 levels was detected in CP/CPPS patients 
compared to controls (p > 0.05) (Figure 2C.1). However, 
by stratifying all studied men into low (<3,000 pg/ml) or 
high (≥3,000 pg/ml) seminal plasma IL-8 concentrations, 
we found that older men possessed significantly higher 
IL-8 concentrations (Figure 2C.2). High IL-8 levels 
(≥3,000 pg/ml) in seminal plasma were also significantly 
associated with high E2 levels in blood, but not in seminal 
plasma (Figure 2C.3 and 2C.4). 
Our data show that ejaculates from both CP/CPPS 
patients and controls contain a considerable number 
of somatic cells expressing genes characteristic only 
for inflammatory i.e. white blood cells (leukocytes). In 
addition to impaired semen parameters, which have been 
previously associated with CP/CPPS, the somatic cells and 
leukocytes isolated from ejaculates may serve as a novel 
source of molecular information about the inflammatory 
state in the prostate of these patients. We also show that 
IL-8-concentrations in seminal plasma increase with age, 
independent from CP/CPPS diagnosis. As such, IL-8 
Figure 1: Characterization of analyzed cohorts with regard to estradiol (E2) and testosterone levels in blood and 
seminal plasma. (A) Age-matched cohorts of healthy men and CP/CPPS patients (A.1) were analyzed regarding the interdependence of 
systemic (in peripheral blood) and local (in seminal plasma) E2 levels to age and to one another. In both, controls (blue filled circles) and 
patients (empty circles) blood E2 was not correlated to age (A.2). In patients, but not in controls, a moderate significant correlation was 
found between seminal plasma E2 and age (A.3). In patients, but not in controls, a highly significant correlation between seminal plasma E2 
and blood E2 was found (A.4); (B) By comparing controls and patients with regard to systemic and local E2 levels, a significant increase of 
E2 were detected in seminal plasma of CP/CPPS men, whereas E2 levels in blood were similar (B.1 and B.2). Striking, considering controls 
and patients together, a highly significant correlation between seminal plasma E2 and deterioration of urinary tract symptoms was found 
(B.3). However, in a separated analysis of controls and patients this correlation was less obvious (B.4). No correlation was found between 
the pain subscore and seminal plasma E2 (B.5); (C) Testosterone was routinely measured in CP/CPPS patients’ peripheral blood. Older 
patients (≥40 years) possessed significantly reduced testosterone levels than younger patients (<40 years) (C.1). Young as well as older 
patients exhibited a significant positive correlation between E2 and testosterone in blood (C.2). In young patients’ seminal plasma E2 and 
testosterone were also significantly correlated, whereas in older patients this correlation was absent (C.3). Abbreviations: **p ≤ 0.01; ns: not 
significant (p > 0.05); CPSI: chronic prostatitis symptom index.
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would be an unreliable parameter to assess the extent of 
inflammation in CP/CPPS patients.
Local epigenetic down-regulation of estrogen 
receptors ESR1 and ESR2 is associated with 
elevated estrogen levels in seminal plasma of CP/
CPPS patients
Significantly elevated levels of E2 were found in 
seminal plasma of CP/CPPS patients and were positively 
correlated to urinary tract symptoms (Figure 1B.2 and 
1B.3). In order to determine potential molecular reasons 
resulting in the local E2-excess in CP/CPPS patients, we 
analyzed somatic cells from ejaculates for gene expression 
and promoter CpG-methylation of the estrogen receptors, 
ESR1 and ESR2, as well as the androgen receptor (AR). 
Hereafter, median values and ranges (minimum to 
maximum) for relative gene expression (delta-delta ct 
value) and promoter methylation (percentage of cells 
fully methylated in analyzed CpGs in ESR1, ESR2 and 
AR promoters) are given. Transcription of both ESR1 and 
ESR2 were significantly decreased in CP/CPPS patients 
(ESR1: 125.9 (range 0 to 2,846.6); ESR2: 379.7 (range 0 to 
4,933.3)) in comparison to healthy controls (ESR1: 537.5 
(range 0 to 6,746.3); ESR2: 955.4 (range 70.3 to 5,226); 
p = 0.019 and p = 0.003, respectively; Mann–Whitney 
U test), whereas AR gene expression was not significantly 
changed (CP/CPPS: 7,454.2 (range 0 to 95,953); controls: 
14,698 (range 815.6 to 10,8074); p > 0.05; Mann–Whitney 
U test) (Figure 3A.1). Methylation analyses revealed 
Figure 2: Analysis of semen parameters susceptible to changes under inflammatory conditions and expression of 
inflammation factors in ejaculated somatic cells. (A) CP/CPPS patients’ semen possessed significantly reduced pH-values (A.1). 
Seminal plasma zinc levels were comparable between controls and patients (A.2). In both, controls and patients, semen zinc concentrations 
were highly significantly negative correlated to pH-values (A.3); (B) CP/CPPS patients’ semen possessed significantly increased number 
of peroxidase positive cells (leukocytes; represent the majority of somatic cells in ejaculates) (B.1). In ejaculated somatic cells cells, 
aromatase (ARO), mast cell chymase (CMA1) and PU.1 (transcription factor of lymphoid and myeloid hematopoietic cells) mRNAs 
levels were not significantly different between CP/CPPS and controls (B.2, B.3 and B.4); (C) Interleukin 8 (IL-8) levels did not differ 
significantly between controls and patients, although a trend for increased IL-8 was visible in CP/CPPS (C.1). Probands possessing very 
high IL-8 levels in semen (at cut-off of 3,000 pg/ml) were significantly older (C.2) and exhibited significantly increased E2 levels in blood 
(C.3), but not in seminal plasma (C.4). Abbreviations: **p ≤ 0.01; ns: not significant (p > 0.05).
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that ESR1 and ESR2 promoters were both significantly 
more methylated in ejaculated somatic cells of CP/CPPS 
patients (ESR1: 1.25% (range 0.25 to 24.5%); ESR2: 2% 
(range 0.5 to 31.5%)) than in controls (ESR1: 1% (range 
0 to 5.25%); ESR2: 1% (range 0.5 to 6.13%); p = 0.004 
and p < 0.001, respectively; Mann–Whitney U test), 
whereas the methylation status of AR was only slightly 
changed (CP/CPPS: 2.4% (range 1.6 to 7.4%); controls: 
1.8% (range 1.2 to 7.2%); p = 0.031; Mann–Whitney 
U test) (Figure 3A.2). Particularly notable was a 
remarkable high methylation degree of ESR1 and ESR2 
promoters (up to 20–30%) in a number of CP/CPPS cases, 
whereas the controls were inconspicuous (Figure 3A.2). 
Leukocytes isolated from blood did not differ 
significantly (p > 0.05) between CP/CPPS patients and 
controls with regard to ESR1 and AR gene expression 
(CP/CPPS: 11 (range 0 to 206.7) and 455 (range 40.8 to 
21,718); controls: 9.4 (range 0 to 260.5) and 2,378 (range 
11.9 to 12,988), respectively) (Figure 3B.1). However, 
CP/CPPS patients exhibited a significantly decreased 
ESR2 expression (25.9 (range 1.1 to 413)) in comparison 
to controls (74.7 (range 0.6 to 4,284); p = 0.016, Mann–
Whitney U test) (Figure 3B.1). Methylation analyses 
revealed a significant difference in ESR1 promoter (CP/
CPPS: 1.25% (range 0 to 7.5%); controls: 1.5% (range 
0.75 to 5%); p = 0.007, Mann–Whitney U test), but not 
in ESR2 (CP/CPPS: 1.1% (range 0.5 to 7.4%); controls: 
1.3% (range 0.9 to 2.9%); p > 0.05) and AR promoter (CP/
CPPS: 2.2% (range 1.4 to 4.2%); controls: 2.2% (range 1.6 
to 7.6%); p > 0.05) (Figure 3B.2). 
In order to show the effect of ESR1 and ESR2 
promoter methylation and demethylation on gene 
expression, prostate cancer cell lines LNCaP, DU145 
and PC3 were treated with 5-aza-2′-deoxycytidine 
(AZA). AZA is a cytosine analog that inhibits the DNA 
methyltransferase activity and induces demethylation 
and reactivation of silenced genes. In PC3 cells, which 
possessed a hypermethylated ESR1 promoter (Figure 
3C.1) and had no ESR1 expression, AZA treatment led to 
re-expression of ESR1 (Figure 3C.2). In the same way, in 
LNCaP cells possessing a hypermethylated ESR2 promoter 
(Figure 3C.1) and gene silencing, AZA treatment led to re-
expression of ESR2 (Figure 3C.2). These results confirm 
that the expression of ESR1 and ESR2 genes is influenced 
by promoter methylation. 
So, our findings in ejaculated somatic cells showed 
that a local (in male genital compartment) epigenetic 
down-regulation of estrogen receptor genes ESR1 and 
ESR2 was characteristic for CP/CPPS patients and 
associated with local estrogen excess in these patients. 
These data suggest that ESR1 and ESR2 methylation 
and expression status in ejaculated somatic cells may be 
suitable molecular markers for CP/CPPS. In contrast, the 
AR was not changed and hence would be less suitable. 
From our analyses in blood we could not obtain a coherent 
picture: CP/CPPS patients showed a lower transcription 
level of ESR2 and, however, a decreased ESR1 methylation 
compared to healthy controls. 
Deterioration of CP/CPPS symptoms and 
elevated C-reactive protein in patients with 
advanced age
In order to evaluate, whether age and the associated 
hormonal changes that occur upon aging, affect the disease 
severity and symptoms of CP/CPPS, we stratified patients 
into two age-groups (separated using the median cohort 
age; <40 years versus ≥40 years) and analyzed with regard 
to C-reactive protein (CRP, a marker of inflammation), 
prostate specific antigen (PSA) and disease severity based 
on CPSI and IPSS (international prostate symptom score) 
questionnaires. CRP was significantly affected, with older 
patients having significantly elevated levels of CRP in 
blood (p ≤ 0.01) (Figure 3D.1). PSA levels and the CPSI 
score were not significantly different in older patients 
compared to younger ones (p > 0.05) (Figure 3D.2 and 
3D.3). However, the IPSS questionnaire score was also 
significantly increased in older CP/CPPS patients (p ≤ 
0.01; Figure 3D.4). 
Impact of mast cells in chronic inflammation of 
the prostate
Mast cells are a type of leukocytes with myeloid 
origin, which are essential in mediating inflammatory 
processes, regulating a variety of both adaptive and 
innate immune responses [26]. Prostate tumors, which are 
frequently accompanied by prostatic inflammation, contain 
significantly elevated numbers of mast cells at the tumor 
interface, with the tumor stroma promoting increased 
mast cell recruitment and activation [16]. Consistent with 
this and other previous studies, we found the presence 
of mast cells in benign prostate hyperplasia (BPH) and 
prostate carcinoma (PCa) tissue samples, demonstrated 
by the presence and release of the mast specific 
protease, tryptase (Figure 4A). PCa samples (n = 4) 
showed a slightly increased number of mast cells in 
comparison to BPH (n = 4) (PCa: 28.7 ± 2.8 versus BPH: 
21.7 ± 1.2, p < 0.05, t-test) (Figure 4A). 
Mast cell lines HMC-1 and LAD2 differ in 
expression and promoter methylation of ESR1 
and ESR2 genes
In prostate tumors it has also been demonstrated that 
mast cell recruitment and activation is induced by estradiol 
(E2) [16]. Our current results revealing increased E2 levels 
in the seminal plasma of CP/CPPS patients (Figure 1B.2), 
along with the expression of mast cell chymase in the 
ejaculated somatic cells of patients and controls (Figure 
2B.3), suggest an involvement of mast cells in CP/CPPS. 
In order to evaluate the effect of increased E2 on mast cell 
Oncotarget19629www.oncotarget.com
function we analyzed two human mast cell lines, HMC-1 
(progenitor-like) and LAD2 (mature), before and after 
treatment with high dose (100 nM) E2 for 24 hours. Both 
lines express the two estrogen receptors, and our initial 
analyses showed that in untreated HMC-1 cells, ESR1 and 
ESR2 promoters were hypermethylated (68% and 92%, 
respectively) and gene transcriptions were accordingly low 
(Figure 4B.1 and 4B.2). These data from the HMC-1 cells 
are reminiscent of what is detectable in ejaculated somatic 
cells from CP/CPPS patients, where significantly lower 
expression of ESR1 and ESR2 and increased promoter 
methylation is observed in comparison to healthy controls 
Figure 3: Epigenetic down-regulation of estrogen receptors ESR1 and ESR2 in CP/CPPS and deterioration of CP/
CPPS symptoms in patients with advanced age. (A) A significant decrease of expression of both estrogen receptor genes (ESR1 
and ESR2) was detected in somatic cells isolated from ejaculates of CP/CPPS patients in comparison to controls (A.1). By analyzing the 
promoter methylation of ESR1 and ESR2 in ejaculated somatic cells, a highly significant increase of cells having methylated ESR1 and 
ESR2 promoters was found in the CP/CPPS group (A.2). In contrast, androgen receptor (AR) gene expression and promoter methylation 
did not differ much between controls and patients (A.1 and A.1); (B) Leukocytes isolated from blood of CP/CPPS and controls did not 
differ in gene expression of ESR1 (B.1). CP/CPPS patients exhibited a reduced ESR2 and AR expression, whereby for ESR2 the difference 
was statistically significant (B.1). Methylation data showed a significant decrease of cells with methylated ESR1 promoter in CP/CPPS 
patients’ blood leukocytes, whereas ESR2 and AR promoters were comparable between patients and controls (B.2); (C) Prostate cancer 
cell lines LNCaP, DU145 and PC3 were analyzed by COBRA in ESR1 and ESR2 promoters. PC3 cells exhibited methylation (m) in ESR1 
promoter (Bsh1236i (CGCG)-specific restriction bands visible under “+”), whereas the other two were unmethylated (u) (C.1, upper gel 
picture). ESR2 promoter was methylated in LNCaP cells and unmethylated in DU145 and PC3 (C.1, bottom gel picture). Treatment with 
5-aza-2′-deoxycytidine (+AZA) led to re-expression of ESR1 in PC3 cells and of ESR2 in LNCaP cells (C.2); (C) Older CP/CPPS patients 
(≥40 years) exhibited extremely increased levels of CRP (C reactive protein) (D.1) and significantly higher IPSS (international prostate 
symptom score) than younger patients (<40 years) (D.4). The CPSI (chronic prostatitis symptom index), however, did not differ between 
younger and older patients (D.3). Prostate specific antigen (PSA) was also not significantly different in the blood of older and younger 
patients (D.2). Abbreviations: **p ≤ 0.01; ns: not significant (p > 0.05).
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(Figure 3A.1 and 3A.2). In contrast, in untreated LAD2 
cells, ESR1 and ESR2 genes were transcribed at high 
levels and the promoters were almost unmethylated (2% 
and 1%) (Figure 4B.1 and 4B.2). The short term (24 h) 
E2 treatment led to a halving of ESR1 and ESR2 gene 
expression in LAD2, and of ESR2 in HMC-1 cells (Figure 
4B.1). No changes were found after 24 h E2 treatment with 
regard to ESR1 and ESR2 promoter methylation in HMC-1 
as well as in LAD2 cells (Figure 4B.2). 
Increased estrogen levels lead to suppression of 
cytokines and chemokines in HMC-1 and their 
activation in LAD2
The expression of a panel of 84 cytokines and 
chemokines was examined in untreated and E2-stimulated 
HMC-1 and LAD2 cells using the RT2 Profiler PCR 
array “Human cytokines and chemokines” (Qiagen). In 
untreated HMC-1 cells, the majority of genes (52 out of 
84, 62%) were expressed at high levels (delta Ct ≤ 10 
in qPCR), whereas in untreated LAD2, only 27 out of 
84 genes (32%) had a high expression and the majority 
(68%) had low expression (delta Ct > 10) (Figure 4C.1). 
Stimulation with E2 had opposite effects in these two 
lines (Figure 4C.2 and 4C.3). While in HMC-1 cells the 
majority of E2-responsive genes was transcriptionally 
suppressed (21 out of 23 responsive genes were at least 
2-fold down-regulated), a number of genes in LAD2 cells 
showed increased expression (15 out of 18 responsive 
genes were at least 2-fold up-regulated). Among the E2-
suppressed genes in HMC-1 cells, XCL1, CCL18, CXCL2 
and BMP7 showed the strongest (6- to 9- fold) down-
regulation (Figure 4C.3 and Supplementary Figure 2). 
Among E2-activated genes in LAD2 cells, IL-8, CXCL2, 
IL22, IL21, MSTN, IFNG and CSF3 showed the 
strongest (4- to 30-fold) up-regulation (Figure 4C.2 and 
Supplementary Figure 2). 
Altogether, different promoter methylation states 
and herewith associated basal activities of ESR1 and 
ESR2 in HMC-1 (progenitor-like) and LAD2 cells 
(mature) associated with very different expression 
profiles of cytokines and chemokines before and after E2 
stimulation. Specifically, in untreated HMC-1 cells, the 
majority of analyzed inflammatory genes was already 
actively transcribed, while, in contrast, in control LAD2 
cells the majority of genes was silenced or transcribed at 
low levels. Treatment with E2 led in HMC-1 mainly to 
immune-suppression, whereas LAD2 cells reacted with 
activation of immune factors. 
The methylation profile of HMC-1 and LAD2 
cells is similar and does not change under short 
term estrogen stimulation 
The methylation profile of 24 genes with well 
documented roles in cytokine biosynthesis was evaluated 
in untreated and E2-stimulated (100 nM, 24 hours) 
mast cells using the EpiTect Methyl II Signature PCR 
array “Human cytokine production” (Qiagen) and 
pyrosequencing (Supplementary Figure 3). LAD2 and 
HMC-1 cells were both found to be hypermethylated in 
the promoters of ELANE, FOXP3, INHA, INHBA, SMAD3, 
CXCL12 and IL-13 (17% to 100%) (Supplementary Figure 
3). Additionally, LAD2 cells were also hypermethylated 
in the STAT5A promoter, and HMC-1 cells in IGF2BP2, 
ESR1, ESR2 and AR promoters (Supplementary Figure 
3). All other genes analyzed were unmethylated. E2 
stimulation did not change the methylation levels of the 
genes examined, except in BCL3 (0% to 61%) and TLR2 
(0% to 56%) in HMC-1 cells, and GATA3 (51% to 0%) 
and INHA (66% to 28%) in LAD2 cells. 
DISCUSSION
CP/CPPS is a disease of all ages and patients are 
characterized by their symptoms. In a large international 
study comprising 1,563 CP/CPPS patients, the mean age 
was 47.2 years (SD - 15.7 years) [27]. In this study the 
included patients were somewhat younger, but generally 
matched other published cohorts. Decreasing testosterone 
levels with age [28] represent a possible confounding 
factor in a study with a wide age range as ours. This fact 
has been addressed by comparing with an age matched 
healthy control population.
The present results demonstrate that estradiol 
(E2) excess in seminal plasma is a characteristic of CP/
CPPS patients and correlates significantly with the NIH-
CPSI urinary tract symptom subscore. The increase in 
local estrogen levels could be explained by elevated 
aromatase expression within the reproductive tissues of 
CP/CPPS patients as this was not apparent in somatic 
cells isolated from ejaculates. Interestingly, in addition to 
locally elevated E2 levels, we found in ejaculated somatic 
cells of CP/CPPS patients a significant down-regulation 
of ESR1 and ESR2 gene expression, which associated 
with a significant higher methylation of ESR1 and ESR2 
promoters. It remains unclear, whether these epigenetic 
changes affect the leukocytes in ejaculates, which 
represent the majority of somatic cells in semen, or other 
somatic cells (e.g. epithelial cells from urogenital tract), 
which can also be present even if in low numbers. Further 
studies should address and clarify this issue. However, we 
could detect a significant higher number of peroxidase-
positive cells (leukocytes) in CP/CPPS patients’ ejaculates 
than in controls. Moreover, in CP/CPPS patients, but not in 
controls, a significant correlation between estradiol levels 
in seminal plasma and in blood was detected, indicating a 
CP/CPPS specific systemic and local deregulation of E2. 
These novel findings in CP/CPPS patients demonstrate 
that estrogen and estrogen receptors’ deregulation may 
play an important role in the chronification of prostatitis 
and, together with our previous results [25], suggest that 
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semen is a suitable source for development of diagnostic 
biomarkers for CP/CPPS. 
In contrast to semen, there were no significant 
differences detectable with regard to systemic (in blood) 
estradiol levels between CP/CPPS and controls. We found 
that regardless of the presence of CP/CPPS, men exhibiting 
high IL-8 levels in seminal plasma (>3,000 pg/ml vs. 
<3,000 pg/ml) were on average significantly older and 
had significantly increased blood estradiol concentrations. 
Thus, IL-8 seems to be an age-dependent factor and must 
be used in the clinical practice with caution. By analyzing 
leukocytes isolated from blood, we found a significantly 
decreased methylation in ESR1 promoter in CP/CPPS, but 
we did not detect any changes in ESR1 gene expression. 
Furthermore, blood leukocytes from CP/CPPS patients 
possessed a significantly decreased ESR2 expression, 
Figure 4: Incidence of mast cells in the prostate, and different effects of estradiol excess on inflammatory gene expression 
in mast cells. (A) Tryptase (mast cell specific protease)-positive foci (marked by arrows) were found to be abundantly present in tumor-
associated stroma of prostate carcinoma (PCa) tissues. Benign prostate hyperplasia (BPH) samples exhibited fewer mast cells (MC #) as it 
is shown in the diagram (A; representative examples for PCa and BPH are shown); (B) Two human mast cell lines, HMC-1 and LAD2, were 
analyzed with regard to gene expression and CpG-promoter methylation of ESR1 and ESR2 before and after short term (24 h) stimulation 
with 100 nM estradiol (E2). Untreated HMC-1 cells possessed low ESR1 and ESR2 expression (B.1) and hypermethylated ESR1 and ESR2 
promoters (60–90%) (B.2). In contrast, untreated LAD2 cells possessed high ESR1 and ESR2 expression (B.1) and unmethylated ESR1 and 
ESR2 promoters (1–2%) (B.2). Expression levels of ESR1 and ESR2 after E2-treatment were 2-fold reduced in LAD2, and ESR2 was 2-fold 
reduced in HMC-1 (B.1). Short term stimulation with E2 did not change the methylation degrees of ESR1 and ESR2 promoters in both 
cell lines; (C) In order to reveal the effect of estradiol excess on transcription profiles of HMC-1 and LAD2 cells, a transcription profiler 
for 84 inflammatory genes was utilized. Untreated LAD2 and HMC-1 cells possessed very different expression profiles (C.1, Control). E2 
stimulation led to diverging reactions in HMC-1, the majority of responsive genes were down-regulated (increase of the percentage of low 
expressed genes, in red), whereas LAD2 the majority of responsive genes were up-regulated (increase of the percentage of high expressed 
genes, in green) (C.1, +100 nM E2). Genes reacting with at least 2-fold gain or loss of expression upon E2 stimulation (green and red arrows, 
respectively) are shown for LAD2 and HMC-1 (C.2 and C.3, see also Supplementary Figures 2 and 3).
Oncotarget19632www.oncotarget.com
whereas ESR2 promoter did not differ from controls with 
regard to the methylation status. At this point we cannot 
deliver a conclusive explanation about the deregulation of 
ESR1 and ESR2 gene activity in peripheral blood of CP/
CPPS patients, and further differential studies on different 
types of white blood cells are needed. It is known that 
ESR1 (or ERα) is expressed in circulating peripheral 
macrophage- and dendritic cell precursors (MDPs) and 
plays a critical role in dendritic cell (DC) maturation 
[29]. In a mouse model it was shown that macrophages, 
a subtype of DCs, had significantly increased TNFα and 
IL-1B levels and that this effect was ERα dependent [30]. 
The potential of estrogenic imbalance to skew dendritic 
cell maturation was shown in postmenopausal women. 
Plasmocytoid dendritic cells of postmenopausal women 
showed reduced toll like receptor 7-mediated response, 
compared to a younger cohort, and this impairment was 
partially reversed by estradiol supplementation [31]. 
DCs develop from circulating monocytes and mediate 
adaptive immunity by antigen-presentation to T-cells, 
which have been connected to autoimmunity in CP/
CPPS. Prostate antigen immunization of wild type mice 
(C57BL/6) resulted in an IL-4/IL-12 dependent infiltration 
of CD4+ T-cells and macrophages [13], positing a role 
for CD4+ T-cells in prostatic inflammation. An earlier 
case-controlled study also showed that peripheral CD4+ 
T-cells isolated from peripheral blood buffy-coats of CP/
CPPS patients had an increased reactivity to prostatic 
alkaline phosphatase and PSA [32]. Thus, the systemic 
deregulation of ESR1 and ESR2 genes found in CP/CPPS 
could indicate a dendritic cell mediated autoimmunity for 
CP/CPPS. If the observed systemic changes are causative 
for CP/CPPS or are merely a response to local prostate 
inflammation remains to be determined. 
The prostate has the highest zinc concentration 
of all organs in the body [33] and semen zinc levels are 
correlated with fertility parameters including alpha-
glycosidase, a function marker of epididymis [34]. 
Semen zinc is mainly derived from prostatic secretions. 
The prostate fluid is known to be rich in citric acid, 
and the solubility of zinc increases with an increasing 
acidity. Accordingly, in semen of CP/CPPS patients 
as well as controls we found a significant negative 
correlation between zinc concentrations and pH-values. 
In a previous study, zinc levels were also found to be 
reduced in ejaculates of CP/CPPS patients [35]. However, 
in our study cohorts we could not detect a difference in 
semen zinc concentrations between CP/CPPS patients 
and controls. This may be due to the fact that only data 
for older (pre-vasectomy) controls were available as 
reference. Nevertheless, zinc plays an important role for 
the immune system [36] and dietary zinc also has the 
potential to alter steroid hormone turnover and modulate 
testosterone aromatization [37]. Moreover, BPH and 
PCa tissues also have significantly reduced zinc levels 
compared to normal prostate tissue [38]. The potential 
of zinc deficiency to skew the inflammatory reaction is 
supported by experiments in pro-myeolid (HL-60) cells, 
which increased production of IL-1B and TNFα after 
zinc depletion [39]. Strikingly, systemic IL-1B and TNFα 
were significantly elevated and positively correlated with 
patient anxiety and depression scores in a large clinical 
study on CP/CPPS patients [40]. Furthermore, zinc 
supplementation to CP/CPPS patients led to a significant 
decrease of their NIH-CPSI score in the follow-up 
observation after 12 weeks [41]. 
Mast cells are resident in the human prostate, and 
have been implicated to play a role in CP/CPPS as well 
as prostate cancer [16, 42]. Significantly, they are also 
estrogen responsive [16]. In order to gain mechanistic 
insight regarding the elevated estrogen levels we observed 
in the seminal plasma of CP/CPPS patients and the 
effect on human mast cells, we used two human mast 
cell lines possessing different expression of the estrogen 
receptors (ERα and ERβ) and stimulated them with a 
high concentration of estradiol (100 nM). These cell 
lines, HMC-1 and LAD2, are extensively characterized 
and represent the gold-standard for studies of mast cell 
function in vitro. Similar to leukocytes in the ejaculates 
of CP/CPPS patients, untreated HMC-1 cells possessed 
epigenetically (through promoter methylation) caused 
low ESR1 and ESR2 gene expression. In contrast, ESR1 
and ESR2 were both actively expressed and the promoters 
were unmethylated in untreated LAD2 cells. The cell lines 
also differ remarkably in their basal inflammatory gene 
expression profile and response to estradiol stimulation. 
In untreated HMC-1 cells 52 out of 84 analyzed 
inflammatory factors were actively transcribed, whereas 
in LAD2 cells only 27 out of 84 were expressed. Estradiol 
stimulation of HMC-1 cells caused a suppression of 
21 inflammatory genes (out of 23 responsive genes in 
total), and in LAD2 cells, an activation of 15 genes (out 
of 18 responsive). HMC-1 and LAD2 cells also vary 
considerably in cell properties and culture conditions. 
LAD2 cells, phenotypically resembling more mature mast 
cells, grow much slower and are more difficult to culture, 
compared to HMC-1 cells, which are immature and more 
progenitor-like. Additionally, a comparison of both cell 
lines with mature skin mast cells (sMC) also reported that 
LAD2 cells are intermediately differentiated, while HMC-
1 cells are very immature malignantly transformed mast 
cells [43]. 
Elevated estrogen levels and altered expression of 
the estrogen receptors, particularly an altered ERα:ERβ 
ratio, are also factors that are associated with prostate 
cancer. Previous reports have proposed that ESR1 and 
ESR2 could have a tumor suppressor role in prostate 
gland. For example, loss of ESR1 transcription and ESR1 
protein by promoter methylation, respectively, increased 
with progression of prostatic disease from BPH to low 
grade and to high grade cancer [44–46].Most reports on 
ESR2 expression concur, that levels decline in localized 
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prostate cancer with increasing grade from prostatic 
intraepithelial neoplasia through low to high grade 
Gleason scores [47–50].The loss of ESR2 expression 
in organ confined prostate cancer has been shown to be 
epigenetically regulated by progressive hypermethylation 
of ESR2 promoter [46, 51]. The capability of estrogen as a 
ligand to down-regulate ERα is well established [52, 53]. 
In the breast cancer MCF-7 cell line it has also been shown 
that the phytoestrogens quercetin and genistein share 
this capability [21], which makes the use of quercetin in 
treatment of CP/CPPS questionable or, at least emphasizes 
the need of an individualized therapy with an involvement 
of molecular analyses prior to treatment. Similar 
regulation of ERβ occurs, but can differ between tissue 
types. A study investigating the effect of estrogen on its 
receptors found estradiol-mediated ERβ down-regulation 
in MCF-7, but up-regulation in human aortic smooth 
muscle cells [54]. These and our current data support the 
growing body of evidence implicating chronic prostatitis 
in the development of prostate malignancy.
In summary, our results demonstrate that estradiol 
excess in seminal plasma is a characteristic of patients with 
CP/CPPS. This is also associated with a local epigenetic 
down-regulation of the estrogen receptors, which is 
traceable in the somatic cells of the ejaculate. Estrogen 
was also shown to alter inflammatory cytokine and 
chemokine expression in mast cells in opposite directions 
depending on the epigenetic status and transcriptional 
activity of estrogen receptors, which in turn are implicated 
in CP/CPPS and prostate cancer development. Overall, 
these novel findings suggest that estrogen action may 
play an important role in the chronification of prostatitis. 
Additionally, these data also suggest that somatic cells 
from the ejaculate could reflect the inflammation status 
of the prostate, and may be a viable resource to develop 
supportive molecular markers for CP/CPPS.
MATERIALS AND METHODS
Collection and analysis of liquid biopsies from 
CP/CPPS patients and healthy controls
Whole blood and semen samples were collected 
from CP/CPPS patients (n = 50, median age 39.76, range 
23–65) and healthy men (controls) without any preexisting 
urological conditions (n = 61, median age 36.77, range 
20–69) in the Clinic of Urology, Pediatric Urology and 
Andrology, JLU Giessen, Germany. The control group 
comprised volunteers (n = 40) and men requesting 
vasectomy (n = 21). The latter cohort was added in order 
to get an age-matched control cohort and to exclude age-
associated effects on hormonal balance. From patients 
undergoing vasectomy, we used pre-vasectomy peripheral 
blood and ejaculates, respectively. All study participants 
gave their written informed consent and the study was 
approved by the Ethics Commission of the JLU Giessen 
(ethical vote, AZ.: 55/13). 
The clinical presentation of CP/CPPS patients 
and healthy volunteers was confirmed according to 
guidelines [7, 55, 56], including the use of the German 
version of the Chronic Prostatitis Symptom Index from 
the National Institute of Health (NIHCPSI) [57] as we 
previously described [25]. Infection was excluded with 
microbiological cultures and gene amplification analysis 
[57, 58]. Since the classification to inflammatory (IIIa) 
and non-inflammatory (IIIb) CP/CPPS might present 
two different stages of the same condition [59], both sub-
categories were included in our patient cohort. 
Blood samples from CP/CPPS patients were 
routinely analyzed for total testosterone, C-reactive protein 
(CRP) and prostate specific antigen (PSA) levels in the 
central laboratory of our university hospital (ADIVA, 
Siemens Health Care, Erlangen, Germany). Estradiol 
concentrations in blood and seminal plasma of patients 
and controls were analyzed separately at the Institute of 
Laboratory Medicine and Pathobiochemistry, Molecular 
Diagnostics, UKGM Giessen. Semen parameters of 
patients and controls were routinely analyzed according 
to the WHO-2010 recommendations [60]. Seminal 
plasma was separated from the cellular fraction by 
centrifugation (5 minutes at 600 g) and analyzed for 
polymorpho-nuclear elastase, IL-8, alpha-glycosidase 
and zinc with standardized methods [25]. The cellular 
fractions (ejaculate pellets) were stored at –80° C and 
used further for isolation of leukocytes (refer below). CP/
CPPS patients and healthy volunteers were examined and 
evaluated based on CPSI, IPSS and HADS questionnaires. 
All clinical and pathological data gathered are summarized 
in Supplementary Figure 1.
Isolation of leukocytes from whole blood and 
ejaculate samples
Frozen (–80° C) EDTA blood samples (3 ml) 
were thawed on ice and incubated for 10 minutes with 5 
volumes of red blood cell lysis buffer (15.5 mM NH4Cl, 
1 mM KHCO3 and 0.01 mM tetra-sodium EDTA in di-
ethyl-pyrocarbonate treated deionized water; pH 7.3). 
Cells were centrifuged (10 minutes at 600 g) and pellets 
were incubated with 1.5 ml fresh buffer on ice for 
another 10 minutes. Blood leukocytes were obtained by 
centrifugation (5 minutes at 600 g). Ejaculate leukocytes 
were isolated from frozen-stored ejaculate pellets by 
density gradient centrifugation. Briefly, ejaculate pellets 
were thawed on ice and dissolved in 600 µl DMEM-F12 
medium (Gibco). Samples were then placed on top of 
a pre-layered Histopaque®1077 gradient (1.5 ml 90% 
+ 1.5 ml 50% + 1.5 ml 20%; all solutions at 4° C) in 
12ml-polypropylene-tubes (Sarstedt) and centrifuged 
(30 minutes at 400 g). The phenol-red from DMEM-F12 
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allowed for convenient identification of resulting phases. 
Upper fraction contained leukocytes, and the pellet 
contained sperm cells. Leukocytes were pelletized by 
centrifugation for 5 minutes at 600 g and 4° C. Leukocytes 
from blood and ejaculates were washed twice with PBS 
and frozen at –80° C until DNA and RNA isolations.
DNA and RNA extractions from leukocytes
Blood and ejaculate leukocyte samples were 
thawed on ice and dissolved in 1ml peqGOLD TriFast™ 
reagent (Peqlab). The aqueous phase was used for RNA 
isolation and DNA was isolated from the organic phase. 
RNA and DNA isolations were performed according to 
the manufacturer’s protocol (Peqlab). RNA was digested 
with 1 unit DNAseI in 20 µl volume following the 
manufacturer’s (NEB) instructions, purified and dissolved 
in 20 µl of DEPC treated nuclease-free water. DNA was 
recovered from the same sample by addition of 0.5 ml Back 
Extraction Buffer (4 M guanidine thiocyanate, 50 mM 
sodium citrate and 1 M Tris) to the organic phase. RNA 
and DNA concentrations were measured on NanoDrop 
1000 (Thermo Scientific) and stored at –80° C until use.
5-aza-2′-deoxycytidine treatment of prostate 
cancer cell lines and COBRA analysis
Human prostate cancer cell lines PC3, LNCaP 
and DU145 were used in order to analyze the effect of 
ESR1 and ESR2 promoter methylation and demethylation, 
respectively, on gene expression. As described in our 
previous study [25], 30% confluent cell plates were treated 
with 5 µM 5-aza-2′-deoxycytidine (Sigma Aldrich) for 72 
hours. On day 4, the cells were harvested and the nucleic 
acids were isolated and subjected for ESR1 and ESR2 
expression analyses (by RT-qPCR as described below) 
and promoter methylation analyses by COBRA (combined 
bisulfite restriction analysis; Table 1) using the CGCG-
specific enzyme Bsh1236i (Thermo Fisher Scientific). 
Estrogen stimulation of HMC-1 and LAD2 cells, 
and RNA and DNA isolations 
Human HMC-1 mast cells (kindly provided by Dr J. 
Butterfield; Mayo Clinic, USA) were cultured as previously 
described [16]. LAD2 cells (kindly provided by Dr A. 
Kirshenbaum; National Institutes of Health, USA) were 
maintained as previously described [61]. Cells were then 
seeded into 10cm dishes at densities of ~0.176 × 106/cm2 
(HMC1, 1 × 107/dish) and ~0.529 × 105/cm2 (LAD2, 3 
× 106/dish). Treatments (100 nM estradiol or ethanol 
vehicle control) were done twice (for DNA and RNA, 
respectively) under the same conditions. After 24 hours, 
cells were washed with PBS (5 minutes centrifugation at 
400 g) and resuspended in 50 µL PBS for DNA isolation 
or 100 µl RNA-later (Sigma) for RNA isolation. For 
DNA extraction, cell pellets were digested for 1 hour with 
0.75 µg/µL proteinase K (Carl Roth) at 56° C. 500 µL of 
Phenol/Chloroform/isoamylalcohol (25:24:1) were added, 
and phase separation was acquired by centrifugation (10 
minutes at 13.000 rpm). DNA samples were precipitated 
with 1 volume isopropanol, 1/10 volume sodium acetate 
(3 M) and 5 µg glycogen. RNA from cell pellets was 
isolated with peqGOLD TriFast™ reagent (Peqlab) 
according to manufacturer’s protocol. RNA and DNA 
concentrations were measured on the NanoDrop-1000 
(Thermo Scientific) and stored at –80° C until use.
Gene expression analyses using RT-qPCR and 
RT² Profiler 
Leukocytes isolated from blood and ejaculates of 
CP/CPPS patients and healthy controls were analyzed for 
relative gene expression of ESR1, ESR2, AR, CMA1, ARO 
and PU.1 by RT-qPCR (reverse transcription followed by 
quantitative real-time PCR) using the CFX96 Touch™ 
RealTime PCR Detection System (Biorad) and RotorGene 
SYBR Green PCR Kit (Qiagen) (Table 1). The house 
keeping gene TUBA1B (alpha-tubulin) was used as 
reference gene (Table 1). An RNA sample isolated from 
blood leukocytes of a healthy donor was used as internal 
standard sample (calibrator). RNA samples (each 2 µg) were 
reverse transcribed in cDNA with MMLV-RT (Promega) 
according to manufacturer’s protocol. The cDNA samples 
were purified with the Nucleotide Removal Kit (Qiagen). 
Quantitative PCRs were performed in duplicates. Relative 
expression levels were calculated with the ΔΔCT method. 
Untreated and E2-stimulated mast cell lines HMC-
1 and LAD2 were analyzed with regard to relative gene 
expression of 84 inflammatory factors using the RT² 
Profiler™ “Human Cytokines and Chemokines PCR 
Array” (Qiagen) (E2-responsive genes are shown in 
Supplementary Figure 2). Briefly, RNA samples (each 
2 µg) were reverse-transcribed with the RT2 First Strand 
Kit (Qiagen). The cDNA samples were purified with the 
Nucleotide Removal Kit (Qiagen) and applied for the 
RT² Profiler™. Relative gene expression levels were 
calculated according to manufacturer’s suggestion by 
using the SA Biosciences PCR Array Data Analysis Web 
portal (Qiagen). Five housekeeping genes (ACTB, B2M, 
GAPDH, HPRT1 and RPLP0) were included. The genes 
B2M, GAPDH and HPRT1 showing the most stable 
results, were chosen as reference genes for normalization 
of values generated by RT² Profiler™. RT-qPCRs for 
ESR1, ESR2, AR and TUB1A were done for HMC-1 and 
LAD2 RNA samples in triplicates as described before. 
CpG-promotor methylation analyses by 
pyrosequencing and EpiTect Methyl II Profiler 
Leukocytes isolated from blood and ejaculates of 
CP/CPPS patients and healthy controls, and mast cell 
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lines HMC-1 and LAD2 (untreated and E2-stimulated) 
were analyzed for CpG-promoter methylation of ESR1, 
ESR2 and AR genes. Therefore, 1 µg DNA was bisulfite-
treated using the EZ DNA Methylation™ Kit (Zymogen). 
Bisulfite-treated DNA samples were subsequently 
amplified and pyrosequenced using appropriate primer 
sets (Table 1, Qiagen) and the PyroMark Q24 System 
(Qiagen). Prior pyrosequencing the PCR products were 
controlled on an agarose gel (2%). Methylation values 
were analyzed using PyroMark Q24 Software (Qiagen; 
quantitative analysis of 4 CpG sites in ESR1, 8 CpGs in 
ESR2 and 5 CpGs in AR). 
Both mast cell lines were analyzed for CpG-
promoter methylation of 22 inflammatory factors using 
the EpiTect Methyl II “Human Cytokine Production 
Signature Panel” (Qiagen) (Supplementary Figure 3). 
Briefly, according to the manufacturer’s protocol, DNA 
samples from control and E2-stimulated HMA-1 and 
LAD2 cells were first incubated with methylation-
dependent restriction enzymes. A subsequent qPCR 
on prefabricated 96-well plates and application of the 
appropriate software (Qiagen) enabled the quantification 
of individual CpG methylation levels. The qPCRs were 
done using the RotorGene SYBR Green PCR Kit (Qiagen) 
and the CFX96 Touch™ RealTime PCR Detection 
System (Biorad). Additionally, HMC-1 and LAD2 cells 
were analyzed using pyrosequencing for CpG-promoter 
methylation of CXCL12, CXCR4 and IL-13 genes using 
appropriate primer sets (Qiagen) (Table 1, Supplementary 
Figure 3).
Detection of mast cell tryptase in PCa and BPH 
tissue samples
Tissue samples from prostate carcinoma (PCa, 
obtained by radical prostatectomy) and benign prostate 
hyperplasia (BPH, obtained by transurethral resection of 
prostate) were collected at the Clinic of Urology, Pediatric 
Urology and Andrology, JLU Giessen, Germany. Patients 
gave their written informed consent for participation 
in a research study. The study was approved by the 
ethical committee of the Medical Faculty, JLU Giessen 
(ethical vote, AZ.: 123/12). Prostate tissue samples were 
characterized at the Institute of Pathology, JLU Giessen. 
Immunohistochemistry was performed on paraffin-
embedded tissue sections. Briefly, after deparaffinization 
with Xylol, the tissue slides were washed with ethanol 
and cooked in antigen retrieval buffer (10% citrate, pH 
= 6.0). After permeabilization, slides were incubated at 
4° C overnight with monoclonal anti-α-Tryptase (1:1000, 
Santa Cruz, sc-59587) in 2% PBT (PBS containing 2% 
Triton X-100). Then, slides were washed thrice with 
2% PBT and incubated for 1 hour with biotinylated 
polyclonal goat α-rabbit IgG (1:200, Dako Denmark A/S, 
E0432). Development was done with VECTASTAIN 
Elite ABC-Peroxidase (Vector Laboratories) using 
3,3′-diaminobenzidine (DAB) enhanced liquid substrate 
systems (Sigma-Aldrich). Tryptase positive mast cells 
were counted in PCa (n = 4) and BPH samples (n = 4) 
in tissue areas of the same size and mean values were 
compared using t-test. 
Table 1: Primer sets used for pyrosequencing, COBRA and RT-qPCR
Method/Gene Upper (5′-3′) Lower (5′-3′) Ta PCR size
Pyrosequencing/ESR1 Hs_ESR1_01_PM PyroMark CpG assay (Qiagen, 4 CpGs) 60 114bp
Pyrosequencing/ESR2 Hs_ESR2_01_PM PyroMark CpG assay (Qiagen, 8 CpGs) 60 192bp
Pyrosequencing/AR Hs_AR_01_PM PyroMark CpG assay (Qiagen, 5 CpGs) 60 167bp
COBRA/ESR1 AGYGTGTTTTYGAGT 
TYGTT
ACTCCCRCAACTCCCTAAAC 60 247bp
COBRA/ESR2 TGTGGGTGGATTAGG 
AGTYG
RCCTACTCTTCRCCCTACAA 60 299bp
RT-qPCR/ESR1 TGCAGGGAGAGGAGTTTGTG GGACAGAAATGTGTACA 
CTCCAGA
60 71bp
RT-qPCR/ESR2 GATGAGGGGAAATGCGTAGA GATCATGGCCTTGACACAGA 60 120bp
RT-qPCR/AR GCAGGAAGCAGTATCCGAAG GACACCGACACTGCCTTACA 60 144bp
RT-qPCR/CMA1 GTCCCACCTGGGAGAATGTG TCTTGCAGAGTGTCTGAGCC 60 80bp
RT-qPCR/ARO AGGAGGTGACCAATGAATCG CACGATAGCACTTTCGTCCA 60 116bp
RT-qPCR/PU.1 GTGCCCTATGACACGGATCT CCAGTAATGGTCGCTATGGCT 60 93bp
RT-qPCR/TUBA1B CGTGCCCCGGGCTGTGTTT GCAGCATCTTCCTTGCCTGTGA 60 117bp
Abbreviations: COBRA: combined bisulfite restricition analysis (Y = C + T; R = A + G); RT-qPCR: reverse transcription 
followed by quantitative real-time PCR; Ta: annealing temperature; PCR size: length of PCR product; ESR1: Estrogen 
Receptor Alpha; ESR2: Estrogen Receptor Beta; AR: Androgen Receptor; CMA1: Human mast cell chymase 1; ARO: 
Aromatase; PU.1: hematopoietic transcription factor SPI1 binding to PU-box; TUBA1B: tubulin alpha 1b.
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Statistical analysis
Statistical analyses were done with SPSS 23.0 
(IBM) and Prism 7.02 (Graphpad). Median values are 
given for age, basic semen parameters, IPSS, CPSI scores 
and biochemical parameters. Median values and ranges 
(minimum-maximum) for mRNA and promoter CpG-
methylation levels are given in Boxplots and shown in 
figures. Non-parametric variables were compared using 
the Mann–Whitney U-test (2-sided). Only p-values ≤ 0.02 
were considered as statistically significant. 
Abbreviations
CP/CPPS: chronic prostatitis chronic pelvic pain 
syndrome; ESR1: estrogen receptor alpha; ESR2: estrogen 
receptor beta; E2: estradiol; AR: androgen receptor; PCa: 
prostate carcinoma; BPH: benign prostate hyperplasia; 
CPSI: chronic prostatitis symptom index; IPSS: 
international prostate symptom score.
Author contributions
US and FW conceptualized and designed the 
study; FW and AP were responsible for daily clinical 
routine and the flow of biological materials; US and TD 
supervised the experimental part; NN, CH, EB and RS 
collected and processed liquid biopsies from patients and 
healthy donors, and acquired clinical data; NN performed 
epigenetic studies on liquid biopsies and mast cell lines 
and statistical data evaluation; SE and GR provided 
estradiol treated mast cell lines; HCS was responsible for 
routine investigation of semen parameters; WW supported 
substantially the infrastructure and scientific network; 
NN, TD, FW and US evaluated and interpreted the data; 
NN and US wrote the manuscript; all authors revised and 
approved the manuscript. 
ACKNOWLEDGMENTS
We thank Mrs. Tania Bloch, Mrs. Kerstin Wilhelm 
and Mrs. Brindusa Schuster for technical assistance in 
semen analysis; Mrs. Julia Wolf for support in patient 
data management; Mrs. Barbara Froehlich for technical 
assistance in RT-qPCR; Mr. Siva Reddy Velagala for IHC 
analyses in PCa and BPH tissue samples; Mrs. Birunthi 
Niranjan and Mrs. Linda Teng for support in E2-treatment 
of mast cell lines; Mrs. Lisa M Teuchert for support in 
collection of patient material. 
CONFLICTS OF INTEREST
The authors declare no competing financial interests.
FUNDING
This study was supported by the German Research 
Foundation (DFG), in the frame of the IRTG1871 
“Molecular pathogenesis of male reproductive disorders” 
(grant to FW, US, WW, SE and GR, project 5).
REFERENCES 
 1. Lepor H. Pathophysiology of benign prostatic hyperplasia 
in the aging male population. Rev Urol. 2005; 7:S3–S11.
 2. NIH. National Cancer Institute - Cancer Stat Facts. Prostate 
Cancer. 2017.
 3. Collins MM, Meigs JB, Barry MJ, Walker Corkery E, 
Giovannucci E, Kawachi I. Prevalence and correlates 
of prostatitis in the health professionals follow-up study 
cohort. J Urol. 2002; 167:1363–1366.
 4. Wagenlehner F, Pilatz A, Linn T, Diemer T, Schuppe HC, 
Schagdarsurengin U, Hossain H, Meinhardt A, Ellem S, 
Risbridger G, Weidner W. Prostatitis and andrological 
implications. Minerva Urol Nefrol. 2013; 65:117–123.
 5. Krieger JN, Nyberg L Jr, Nickel JC. NIH consensus 
definition and classification of prostatitis. JAMA. 1999; 
282:236–37.
 6. Magistro G, Wagenlehner F, Grabe M, Weidner W, Stief 
C, Nickel JC. Contemporary management of chronic 
prostatitis/ chronic pelvic pain syndrome. Eur Urol. 2016; 
69:286–297.
 7. Schaeffer AJ, Knauss JS, Landis JR, Propert KJ, Alexander 
RB, Litwin MS, Nickel JC, O’Leary MP, Nadler RB, 
Pontari MA, Shoskes DA, Zeitlin SI, Fowler JE Jr, et al, and 
Chronic Prostatitis Collaborative Research Network Study 
Group. Leukocyte and bacterial counts do not correlate with 
severity of symptoms in men with chronic prostatitis: The 
National Institutes of Health Chronic Prostatitis Cohort 
Study. J Urol. 2002; 168:1048–1053.
 8. Shoskes D, Nickel JC, Dolinga R, Prots D. Clinical 
phenotyping of patients with chronic prostatitis/ chronic 
pelvic pain syndrome and correlation with symptom 
severity. Urology. 2009; 73:538–542.
 9. Magri V, Wagenlehner F, Perletti G, Schneider S, Marras 
E, Naber KG, Weidner W. Use of the UPOINT chronic 
prostatitis/chronic pelvic pain syndrome classification in 
European patient cohorts: sexual function domain improves 
correlations. J Urol. 2010; 184:2339–2345.
10. Bonkhoff H, Berges R. The evolving role of oestrogens 
and their receptors in the development and progression of 
prostate cancer. Eur Urol. 2009; 55:533–42.
11. Dimitrakov J, Joffe HV, Soldin SJ, Bolus R, Buffington 
CA, Nickel JC. Adrenocortical hormone abnormalities in 
men with chronic prostatitis/chronic pelvic pain syndrome. 
Urology. 2008; 71:261–266.
Oncotarget19637www.oncotarget.com
12. Byun JS, Yoon TK, Rhee HW, Kim JH, Shin JS, Kim HS, 
Bak CW. Chronic pelvic pain syndrome and semen quality 
of Korean men in their fourth decade. J Androl. 2012; 
33:876–885.
13. Motrich RD, Breser ML, Sanchez LR, Godoy GJ, Prinz 
I, Rivero VE. IL-17 is not essential for inflammation and 
chronic pelvic pain development in an experimental model 
of chronic prostatitis/chronic pelvic pain syndrome. Pain. 
2016; 157:585–597.
14. Bernoulli J, Yatkin E, Laakso A, Anttinen M, Bosland 
M, Vega K, Kallajoki M, Santti R, Pylkkänen L. 
Histopathological evidence for an association of 
inflammation with ductal pin-like lesions but not with 
ductal adenocarcinoma in the prostate of the noble rat. 
Prostate. 2008; 68:728–739. 
15. Ellem SJ, Wang H, Poutanen M, Risbridger GP. Increased 
endogenous estrogen synthesis leads to the sequential 
induction of prostatic inflammation (prostatitis) 
and prostatic pre-malignancy. Am J Pathol. 2009; 
175:1187–1199.
16. Ellem SJ, Taylor RA, Furic L, Larsson O, Frydenberg M, 
Pook D, Pedersen J, Cawsey B, Trotta A, Need E, Buchanan 
G, Risbridger GP. A pro-tumourigenic loop at the human 
prostate tumour interface orchestrated by oestrogen, 
CXCL12 and mast cell recruitment. J Pathol. 2014; 
234:86–98.
17. Done JD, Rudick CN, Quick ML, Schaeffer AJ, Thumbikat 
P. Role of mast cells in male chronic pelvic pain. J Urol. 
2012; 187:1473–1482.
18. De Rose AF, Gallo F, Giglio M, Carmignani G. Role of 
mepartricin in category III chronic nonbacterial prostatitis/
chronic pelvic pain syndrome: a randomized prospective 
placebo-controlled trial. Urology. 2004; 63:13–16.
19. Miodini P, Fioravanti L, Di Fronzo G, Cappelletti V. The 
two phyto-oestrogens genistein and quercetin exert different 
effects on oestrogen receptor function. Br J Cancer. 1999; 
80:1150–1155.
20. Shoskes DA, Zeitlin SI, Shahed A, Rajfer J. Quercetin in 
men with category III chronic prostatitis: a preliminary 
prospective, double-blind, placebo-controlled trial. Urology. 
1999; 54:960–963.
21. Maggiolini M, Bonofiglio D, Marsico S, Panno ML, Cenni 
B, Picard D, Ando S. Estrogen receptor alpha mediates the 
proliferative but not the cytotoxic dose-dependent effects 
of two major phytoestrogens on human breast cancer cells. 
Mol Pharmacol. 2001; 60:595–602.
22. Saijo K, Collier JG, Li AC, Katzenellenbogen JA, Glass 
CK. An ADIOL-ERβeta-CtBP transrepression pathway 
negatively regulates microglia-mediated inflammation. 
Cell. 2011; 145:584–595.
23. Jacenik D, Cygankiewicz AI, Fichna J, Mokrowiecka A, 
Małecka-Panas E, Krajewska WM. Estrogen signaling 
deregulation related with local immune response 
modulation in irritable bowel syndrome. Mol Cell 
Endocrinol. 2017S0303-7207(17)30416-1.
24. Zhang ZY, Schluesener HJ. HDAC inhibitor MS-275 
attenuates the inflammatory reaction in rat experimental 
autoimmune prostatitis. Prostate. 2012; 72:90–99. https://
doi.org/10.1002/pros.21410.
25. Schagdarsurengin U, Teuchert LM, Hagenkotter C, Nesheim 
N, Dansranjavin T, Schuppe HC, Gies S, Pilatz A, Weidner 
W, Wagenlehner FM. Chronic Prostatitis Affects Male 
Reproductive Health and Is Associated with Systemic and 
Local Epigenetic Inactivation of C-X-C Motif Chemokine 
12 Receptor C-X-C Chemokine Receptor Type 4. Urol Int. 
2017; 98:89–101.
26. He A, Shi GP. Mast cell chymase and tryptase as targets 
for cardiovascular and metabolic diseases. Curr Pharm Des. 
2013; 19:1114–1125.
27. Wagenlehner FM, van Till JW, Magri V, Perletti G, Houbiers 
JG, Weidner W, Nickel JC. National Institutes of Health 
Chronic Prostatitis Symptom Index (NIH-CPSI) symptom 
evaluation in multinational cohorts of patients with chronic 
prostatitis/chronic pelvic pain syndrome. Eur Urol. 2013; 
63:953–9.
28. Beutel ME, Wiltink J, Hauck EW, Auch D, Behre HM, 
Brähler E, Weidner W, and Hypogonadism Investigator 
Group. Correlations between hormones, physical, and 
affective parameters in aging urologic outpatients. Eur Urol. 
2005; 47:749–55.
29. Laffont S, Seillet C, Guery JC. Estrogen Receptor-
Dependent Regulation of Dendritic Cell Development and 
Function. Front Immunol. 2017; 8:108.
30. Calippe B, Douin-Echinard V, Delpy L, Laffargue M, 
Lelu K, Krust A, Pipy B, Bayard F, Arnal JF, Guery JC, 
Gourdy P. 17Beta-estradiol promotes TLR4-triggered 
proinflammatory mediator production through direct 
estrogen receptor alpha signaling in macrophages in vivo. 
J Immunol. 2010; 185:1169–1176.
31. Seillet C, Laffont S, Tremollieres F, Rouquie N, Ribot C, 
Arnal JF, Douin-Echinard V, Gourdy P, Guery JC. The 
TLR-mediated response of plasmacytoid dendritic cells 
is positively regulated by estradiol in vivo through cell-
intrinsic estrogen receptor alpha signaling. Blood. 2012; 
119:454–464.
32. Kouiavskaia DV, Southwood S, Berard CA, Klyushnenkova 
EN, Alexander RB. T-cell recognition of prostatic peptides 
in men with chronic prostatitis/chronic pelvic pain 
syndrome. J Urol. 2009; 182:2483–2489.
33. Zaichick V, Sviridova TV, Zaichick SV. Zinc in the human 
prostate gland: normal, hyperplastic and cancerous. Int Urol 
Nephrol. 1997; 29:565–74.
34. Mankad M, Sathawara NG, Doshi H, Saiyed HN, Kumar S. 
Seminal plasma zinc concentration and alpha-glucosidase 
Oncotarget19638www.oncotarget.com
activity with respect to semen quality. Biol Trace Elem Res. 
2006; 110:97–106.
35. Condorelli RA, Russo GI, Calogero AE, Morgia G, La 
Vignera S. Chronic prostatitis and its detrimental impact 
on sperm parameters: a systematic review and meta-
analysis. J Endocrinol Invest. 2017; 40:1209–18. https://
doi.org/10.1007/s40618-017-0684-0.
36. Gammoh NZ, Rink L. Zinc in Infection and Inflammation. 
Nutrients. 2017; 9.
37. Om AS, Chung KW. Dietary zinc deficiency alters 5 
alpha-reduction and aromatization of testosterone and 
androgen and estrogen receptors in rat liver. J Nutr. 1996; 
126:842–848.
38. Christudoss P, Selvakumar R, Fleming JJ, Gopalakrishnan 
G. Zinc status of patients with benign prostatic hyperplasia 
and prostate carcinoma. Indian J Urol. 2011; 27:14–18.
39. Wessels I, Haase H, Engelhardt G, Rink L, Uciechowski P. 
Zinc deficiency induces production of the proinflammatory 
cytokines IL-1beta and TNFalpha in promyeloid cells 
via epigenetic and redox-dependent mechanisms. J Nutr 
Biochem. 2013; 24:289–297.
40. Hu C, Yang H, Zhao Y, Chen X, Dong Y, Li L, Dong Y, Cui 
J, Zhu T, Zheng P, Lin CS, Dai J. The role of inflammatory 
cytokines and ERK1/2 signaling in chronic prostatitis/
chronic pelvic pain syndrome with related mental health 
disorders. Sci Rep. 2016; 6:28608.
41. Goodarzi D, Cyrus A, Baghinia MR, Kazemifar AM, 
Shirincar M. The efficacy of zinc for treatment of chronic 
prostatitis. Acta Med Indones. 2013; 45:259–264.
42. Roman K, Done JD, Schaeffer AJ, Murphy SF, Thumbikat 
P. Tryptase-PAR2 axis in experimental autoimmune 
prostatitis, a model for chronic pelvic pain syndrome. Pain. 
2014; 155:1328–1338.
43. Guhl S, Babina M, Neou A, Zuberbier T, Artuc M. Mast 
cell lines HMC-1 and LAD2 in comparison with mature 
human skin mast cells--drastically reduced levels of 
tryptase and chymase in mast cell lines. Exp Dermatol. 
2010; 19:845–847.
44. Li LC, Chui R, Nakajima K, Oh BR, Au HC, Dahiya R. 
Frequent methylation of estrogen receptor in prostate 
cancer: correlation with tumor progression. Cancer Res. 
2000; 60:702–706.
45. Lau KM, LaSpina M, Long J, Ho SM. Expression of 
estrogen receptor (ER)-alpha and ER-beta in normal 
and malignant prostatic epithelial cells: regulation by 
methylation and involvement in growth regulation. Cancer 
Res. 2000; 60:3175–3182.
46. Daniels G, Gellert LL, Melamed J, Hatcher D, Li Y, Wei J, 
Wang J, Lee P. Decreased expression of stromal estrogen 
receptor α and β in prostate cancer. Am J Transl Res. 2014; 
6:140–146.
47. Leav I, Lau KM, Adams JY, McNeal JE, Taplin ME, Wang 
J, Singh H, Ho SM. Comparative studies of the estrogen 
receptors beta and alpha and the androgen receptor in 
normal human prostate glands, dysplasia, and in primary 
and metastatic carcinoma. Am J Pathol. 2001; 159:79–92.
48. Fujimura T, Takahashi S, Urano T, Ogawa S, Ouchi Y, 
Kitamura T, Muramatsu M, Inoue S. Differential expression 
of estrogen receptor beta (ERβeta) and its C-terminal 
truncated splice variant ERβetacx as prognostic predictors 
in human prostatic cancer. Biochem Biophys Res Commun. 
2001; 289:692–699.
49. Pasquali D, Rossi V, Esposito D, Abbondanza C, Puca GA, 
Bellastella A, Sinisi AA. Loss of estrogen receptor beta 
expression in malignant human prostate cells in primary 
cultures and in prostate cancer tissues. J Clin Endocrinol 
Metab. 2001; 86:2051–2055.
50. Horvath LG, Henshall SM, Lee CS, Head DR, Quinn DI, 
Makela S, Delprado W, Golovsky D, Brenner PC, O’Neill 
G, Kooner R, Stricker PD, Grygiel JJ, et al. Frequent loss of 
estrogen receptor-beta expression in prostate cancer. Cancer 
Res. 2001; 61:5331–5335.
51. Zhu X, Leav I, Leung YK, Wu M, Liu Q, Gao Y, McNeal 
JE, Ho SM. Dynamic regulation of estrogen receptor-
beta expression by DNA methylation during prostate 
cancer development and metastasis. Am J Pathol. 2004; 
164:2003–2012.
52. Santagati S, Gianazza E, Agrati P, Vegeto E, Patrone C, 
Pollio G, Maggi A. Oligonucleotide squelching reveals 
the mechanism of estrogen receptor autologous down-
regulation. Mol Endocrinol. 1997; 11:938–949.
53. Ellison-Zelski SJ, Solodin NM, Alarid ET. Repression 
of ESR1 through actions of estrogen receptor alpha and 
Sin3A at the proximal promoter. Mol Cell Biol. 2009; 
29:4949–4958. 
54. Barchiesi F, Jackson EK, Imthurn B, Fingerle J, Gillespie 
DG, Dubey RK. Differential regulation of estrogen receptor 
subtypes alpha and beta in human aortic smooth muscle 
cells by oligonucleotides and estradiol. J Clin Endocrinol 
Metab. 2004; 89:2373–81.
55. Nickel JC, Nyberg LM, Hennenfent M. Research guidelines 
for chronic prostatitis: consensus report from the first 
National Institutes of Health International Prostatitis 
Collaborative Network. Urology. 1999; 54:229–233.
56. Lotti F, Corona G, Mondaini N, Maseroli E, Rossi M, 
Filimberti E, Noci I, Forti G, Maggi M. Seminal, clinical 
and colour-Doppler ultrasound correlations of prostatitis-
like symptoms in males of infertile couples. Andrology. 
2014; 2:30–41.
57. Hochreiter W, Ludwig M, Weidner W, Wagenlehner F, Naber 
K, Eremenco S, Arnold B. National Institutes of Health 
(NIH) Chronic Prostatitis Symptom Index. The German 
version. [Article in German] Urologe A. 2001; 40:16–7.
58. Pilatz A, Hossain H, Kaiser R, Mankertz A, Schüttler 
CG, Domann E, Schuppe HC, Chakraborty T, Weidner 
W, Wagenlehner F. Acute epididymitis revisited: impact 
Oncotarget19639www.oncotarget.com
of molecular diagnostics on etiology and contemporary 
guideline recommendations. Eur Urol. 2015; 68:428–435.
59. Xiao J, Ren L, Lv H, Ding Q, Lou S, Zhang W, Dong Z. 
Atypical microorganisms in expressed prostatic secretion 
from patients with chronic prostatitis/chronic pelvic pain 
syndrome: microbiological results from a case-control 
study. Urol Int. 2013; 91:410–416.
60. WHO. WHO Laboratory Manual for the Examination and 
Processing of Human Semen. Geneva. 2010.
61. Kirshenbaum AS, Akin C, Wu Y, Rottem M, Goff JP, 
Beaven MA, Rao VK, Metcalfe DD. Characterization of 
novel stem cell factor responsive human mast cell lines 
LAD 1 and 2 established from a patient with mast cell 
sarcoma/leukemia; activation following aggregation of 
FcepsilonRI or FcgammaRI. Leuk Res. 2003; 27:677–682.
